<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01852032</url>
  </required_header>
  <id_info>
    <org_study_id>221183</org_study_id>
    <nct_id>NCT01852032</nct_id>
  </id_info>
  <brief_title>Computed Tomography Versus Standard 2D Mammography Versus 3D Tomosynthesis</brief_title>
  <official_title>Computed Tomography Versus Standard 2D Mammography Versus 3D Tomosynthesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hologic, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the imaging performance of an investigational breast
      computed tomography (CT) scanner, built at UC Davis, with that of an FDA-Approved breast
      tomosynthesis scanner (capable of producing standard 2-D mammography and 3-D tomosynthesis
      images), built by Hologic, Incorporated, in a group of patients with suspected breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aim of this study is the comparison of Beta values of several different CT and
      Tomosynthesis views (Beta of CT Sagittal View, Beta of CT Coronal View, Beta of CT Axial
      View, Beta of Tomosynthesis Craniocaudal View, Beta of Tomosynthesis Medial Lateral Oblique
      View). Lower Beta values correspond to better image quality (less noise, increased cancer
      detection).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">March 4, 2016</completion_date>
  <primary_completion_date type="Actual">March 4, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Beta of CT Coronal View</measure>
    <time_frame>Day 1</time_frame>
    <description>frequency range corresponding to noise power spectrum (NPS) where beta = NPS(f) = af^-B.
beta is calculated as noise corresponding to frequency. The values of the exponent, beta, range from 1.5 to 3.5 Lower Beta values correspond to better image quality (less noise, increased cancer detection).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Beta of CT Sagittal View</measure>
    <time_frame>Day 1</time_frame>
    <description>frequency range corresponding to noise power spectrum (NPS) where beta = NPS(f) = af^-B.
beta is calculated as noise corresponding to frequency. The values of the exponent, beta, range from 1.5 to 3.5 Lower Beta values correspond to better image quality (less noise, increased cancer detection).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Beta of CT Axial View</measure>
    <time_frame>Day 1</time_frame>
    <description>frequency range corresponding to noise power spectrum (NPS) where beta = NPS(f) = af^-B.
beta is calculated as noise corresponding to frequency. The values of the exponent, beta, range from 1.5 to 3.5 Lower Beta values correspond to better image quality (less noise, increased cancer detection).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Beta of Tomosynthesis Craniocaudal View</measure>
    <time_frame>Day 1</time_frame>
    <description>frequency range corresponding to noise power spectrum (NPS) where beta = NPS(f) = af^-B.
beta is calculated as noise corresponding to frequency. The values of the exponent, beta, range from 1.5 to 3.5 Lower Beta values correspond to better image quality (less noise, increased cancer detection).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Beta of Tomosynthesis Medial Lateral Oblique View</measure>
    <time_frame>Day 1</time_frame>
    <description>frequency range corresponding to noise power spectrum (NPS) where beta = NPS(f) = af^-B.
beta is calculated as noise corresponding to frequency. The values of the exponent, beta, range from 1.5 to 3.5 Lower Beta values correspond to better image quality (less noise, increased cancer detection).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Breast cancer Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tomosynthesis Breast Scanning is done and breast CT Scanning is done.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Tomosynthesis Breast Scanning</intervention_name>
    <description>The breast is positioned and compressed the same way it is in a conventional mammogram using a compression paddle device. The subject will be instructed to hold their breath and not move during the 7- second 3-D tomosynthesis acquisition. The affected breast is positioned with MLO compression. The radiation dose levels for each scan are equivalent to mammography</description>
    <arm_group_label>Breast cancer Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Breast CT Scanning</intervention_name>
    <description>CT scanning will be performed before and after I.V. iodine contrast injection. The subject will lie prone on a large table (which is covered by a foam pad), and she will place the breast to be scanned in a small hole in that tabletop. The hole is surrounded by a soft neoprene &quot;hammock,&quot; which will allow the subject's entire upper torso to slump into the scan plane of the device. After positioning of the affected breast by a female mammography technologist, the subject will be instructed to hold their breath for 16 seconds and the pre-contrast scan will commence. There will be no breast compression. Other than the sound of the relatively noisy x-ray system in the room, the subject will not feel or sense any aspect of this scan.</description>
    <arm_group_label>Breast cancer Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  35 years of age or older

          -  While male patients will not be explicitly excluded, it is expected that all patients
             in this study will be women

          -  Diagnostic findings from prior mammography suspicious for, or highly suggestive of,
             breast malignancy -BIRADS (Breast Imaging Reporting and Data System) categories 4 and
             5

          -  Scheduled for ultrasound or stereotactic core biopsy

          -  Ability to lie still on a table top for up to 10 minutes, longer than the typical
             breast CT duration.

          -  Ability to understand risks, procedures, and benefits involved

        Exclusion Criteria:

          -  Recent breast biopsy

          -  History of breast augmentation implant

          -  Pregnant or Positive urine pregnancy test (UPT) or currently breast-feeding

          -  History of moderate or severe adverse reaction to iodinated contrast injection

          -  Recent serum creatinine â‰¥ 1.5 mg/dL

          -  History of Diabetes Mellitus

          -  Currently taking Glucophage or Glucovance (Metformin)

          -  History of chronic asthma

          -  History of allergy to iodine

          -  Multiple food and/or drug allergy

          -  Renal disease

          -  History of pulmonary disease, phobia of breath holding, or other condition that could
             prevent the subject from being able to perform the 16 second breath hold
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John M Boone, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2012</study_first_submitted>
  <study_first_submitted_qc>May 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2013</study_first_posted>
  <results_first_submitted>February 13, 2018</results_first_submitted>
  <results_first_submitted_qc>February 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 16, 2018</results_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Breast Cancer Patients</title>
          <description>Tomosynthesis Breast Scanning is done and breast CT Scanning is done.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Female participants over the age of 35 with suspected breast cancer</population>
      <group_list>
        <group group_id="B1">
          <title>Breast Cancer Patients</title>
          <description>Tomosynthesis Breast Scanning is done and breast CT Scanning is done.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>greater than 35 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Beta of CT Coronal View</title>
        <description>frequency range corresponding to noise power spectrum (NPS) where beta = NPS(f) = af^-B.
beta is calculated as noise corresponding to frequency. The values of the exponent, beta, range from 1.5 to 3.5 Lower Beta values correspond to better image quality (less noise, increased cancer detection).</description>
        <time_frame>Day 1</time_frame>
        <population>Participants with suspected breast cancer</population>
        <group_list>
          <group group_id="O1">
            <title>Breast Cancer Patients</title>
            <description>Tomosynthesis Breast Scanning is done and breast CT Scanning is done.</description>
          </group>
        </group_list>
        <measure>
          <title>Beta of CT Coronal View</title>
          <description>frequency range corresponding to noise power spectrum (NPS) where beta = NPS(f) = af^-B.
beta is calculated as noise corresponding to frequency. The values of the exponent, beta, range from 1.5 to 3.5 Lower Beta values correspond to better image quality (less noise, increased cancer detection).</description>
          <population>Participants with suspected breast cancer</population>
          <units>power-law slope(B)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" spread="0.424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Beta of CT Sagittal View</title>
        <description>frequency range corresponding to noise power spectrum (NPS) where beta = NPS(f) = af^-B.
beta is calculated as noise corresponding to frequency. The values of the exponent, beta, range from 1.5 to 3.5 Lower Beta values correspond to better image quality (less noise, increased cancer detection).</description>
        <time_frame>Day 1</time_frame>
        <population>Participants with suspected breast cancer</population>
        <group_list>
          <group group_id="O1">
            <title>Breast Cancer Patients</title>
            <description>Tomosynthesis Breast Scanning is done and breast CT Scanning is done.</description>
          </group>
        </group_list>
        <measure>
          <title>Beta of CT Sagittal View</title>
          <description>frequency range corresponding to noise power spectrum (NPS) where beta = NPS(f) = af^-B.
beta is calculated as noise corresponding to frequency. The values of the exponent, beta, range from 1.5 to 3.5 Lower Beta values correspond to better image quality (less noise, increased cancer detection).</description>
          <population>Participants with suspected breast cancer</population>
          <units>power-law slope(B)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="0.352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Beta of CT Axial View</title>
        <description>frequency range corresponding to noise power spectrum (NPS) where beta = NPS(f) = af^-B.
beta is calculated as noise corresponding to frequency. The values of the exponent, beta, range from 1.5 to 3.5 Lower Beta values correspond to better image quality (less noise, increased cancer detection).</description>
        <time_frame>Day 1</time_frame>
        <population>Participants with suspected breast cancer</population>
        <group_list>
          <group group_id="O1">
            <title>Breast Cancer Patients</title>
            <description>Tomosynthesis Breast Scanning is done and breast CT Scanning is done.</description>
          </group>
        </group_list>
        <measure>
          <title>Beta of CT Axial View</title>
          <description>frequency range corresponding to noise power spectrum (NPS) where beta = NPS(f) = af^-B.
beta is calculated as noise corresponding to frequency. The values of the exponent, beta, range from 1.5 to 3.5 Lower Beta values correspond to better image quality (less noise, increased cancer detection).</description>
          <population>Participants with suspected breast cancer</population>
          <units>power-law slope(B)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.79" spread="0.397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Beta of Tomosynthesis Craniocaudal View</title>
        <description>frequency range corresponding to noise power spectrum (NPS) where beta = NPS(f) = af^-B.
beta is calculated as noise corresponding to frequency. The values of the exponent, beta, range from 1.5 to 3.5 Lower Beta values correspond to better image quality (less noise, increased cancer detection).</description>
        <time_frame>Day 1</time_frame>
        <population>Participants with suspected breast cancer</population>
        <group_list>
          <group group_id="O1">
            <title>Breast Cancer Patients</title>
            <description>Tomosynthesis Breast Scanning is done and breast CT Scanning is done.</description>
          </group>
        </group_list>
        <measure>
          <title>Beta of Tomosynthesis Craniocaudal View</title>
          <description>frequency range corresponding to noise power spectrum (NPS) where beta = NPS(f) = af^-B.
beta is calculated as noise corresponding to frequency. The values of the exponent, beta, range from 1.5 to 3.5 Lower Beta values correspond to better image quality (less noise, increased cancer detection).</description>
          <population>Participants with suspected breast cancer</population>
          <units>power-law slope(B)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.06" spread="0.361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Beta of Tomosynthesis Medial Lateral Oblique View</title>
        <description>frequency range corresponding to noise power spectrum (NPS) where beta = NPS(f) = af^-B.
beta is calculated as noise corresponding to frequency. The values of the exponent, beta, range from 1.5 to 3.5 Lower Beta values correspond to better image quality (less noise, increased cancer detection).</description>
        <time_frame>Day 1</time_frame>
        <population>Participants with suspected breast cancer</population>
        <group_list>
          <group group_id="O1">
            <title>Breast Cancer Patients</title>
            <description>Tomosynthesis Breast Scanning is done and breast CT Scanning is done.</description>
          </group>
        </group_list>
        <measure>
          <title>Beta of Tomosynthesis Medial Lateral Oblique View</title>
          <description>frequency range corresponding to noise power spectrum (NPS) where beta = NPS(f) = af^-B.
beta is calculated as noise corresponding to frequency. The values of the exponent, beta, range from 1.5 to 3.5 Lower Beta values correspond to better image quality (less noise, increased cancer detection).</description>
          <population>Participants with suspected breast cancer</population>
          <units>power-law slope(B)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.10" spread="0.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Breast Cancer Patients</title>
          <description>Tomosynthesis Breast Scanning is done and breast CT Scanning is done.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John Brock Staff Research Associate</name_or_title>
      <organization>UC Davis</organization>
      <phone>916-734-3101</phone>
      <email>jmbrock@ucdavis.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

